Geovax Labs Stock News

GeoVax Labs Inc (NASDAQ: GOVX ) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the safety and effectiveness of GEO-CM04S1 compared to the Pfizer Inc (NASDAQ: PFE ) / BioNTech SE (NASDAQ: BNTX ) in immunosuppressed patients with blood cancer. The other trial is testing GEO-CM04S1 as a booster in healthy adults … Full story available on Benzinga.com

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2021 Results - Earnings Call Transcript

Geovax Labs Inc (GOVX) shares closed today 11.5% lower than it did at the end of yesterday. The stock is currently down 23.5% year-to-date, down 40.4% over the past 12 months, and down 30.8% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $3.58 and as low as $2.64 this week.Shares closed 68.2% below its 52-week high and 4.9% above its 52-week low.Trading volume this week was 0.2% higher than the 10-day average and 13.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 880.9% The company's stock price performance over the past 12 months lags the peer average by 129.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Geovax Labs Inc (GOVX) shares closed today 11.5% lower than it did at the end of yesterday. The stock is currently down 23.5% year-to-date, down 38.3% over the past 12 months, and down 30.8% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $3.58 and as low as $2.64 this week.Shares closed 68.2% below its 52-week high and 4.9% above its 52-week low.Trading volume this week was 6.0% higher than the 10-day average and 2.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 14.2% lower than its 5-day moving average, 24.5% lower than its 20-day moving average, and 30.6% lower than its 90-day moving average. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 880.9% The company's stock price performance over the past 12 months lags the peer average by 106.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ATI Physical Therapy (ATIP) +16%. Cardiovascular Systems (CSII) +14%. Acutus Medical (AFIB) -9%. GeoVax Labs (GOVX) -9%.

GeoVax Labs (GOVX) is raising ~$10M from a single institutional investor through a private placement of ~707K common shares, 236K pre-funded warrants to buy common stock and

Geovax Labs Inc (GOVX) shares closed 3.7% lower than its previous 52 week low, giving the company a market cap of $20M. The stock is currently down 9.4% year-to-date, down 38.1% over the past 12 months, and down 18.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 41.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 356.0% The company's stock price performance over the past 12 months lags the peer average by 137.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

GeoVax Labs <> retained CATO SMS to manage GeoVax’s ongoing phase 1/2 trial of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell…

GOVX is uniquely positioned with its Phase 2 COVID-19 vaccine candidate for immunocompromised individuals. It has also started a Phase 2 trial as a booster vaccine for the general population. In addit

GeoVax Labs Inc (NASDAQ: GOVX) initiated vaccine dosing in the Phase 2 portion of its Phase 1/2 trial of COH04S1 COVID-19 vaccine to target both the spike (S) and nucleocapsid (N) proteins. The Pha

Shares of GeoVax Labs Inc. GOVX, -1.76% were down 1.4% in trading on Wednesday after the company said it began a Phase 2 clinical trial for its COVID-19 booster candidate.

Vanguard Group Inc. raised its holdings in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) by 407.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 256,621 shares of the companys stock after buying an additional 206,070 shares during the period. Vanguard Group Inc.s holdings in GeoVax Labs were worth $1,283,000 as of its most recent filing [] The post Vanguard Group Inc. Has $1.28 Million Stock Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) appeared first on ETF Daily News .

Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?

The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 35% pre-market today. This is why it happened.

NEW YORK , Nov. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOVX, SOFI, RIOT, NCLH, and TLRY. Full story available on Benzinga.com